Pharmaceutical

IMS predicts $1T global drug market by 2017

IMS predicts $1T global drug market by 2017

By

The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.

New York Magazine examines cancer drug pricing

New York Magazine examines cancer drug pricing

A wide-ranging piece recounts the pushback from oncologists that led to a decrease in the price of Zaltrap.

GSK breaks cloud cover with financial results

GSK breaks cloud cover with financial results

By

GlaxoSmithKline second-quarter sales rose 2% over the same period last year. CEO Andrew Witty says it is too early to tally the impact of China's corruption allegations.

Business briefs: GSK and Sanofi, plus state legislative news

GlaxoSmithKline says it is scaling back on acquisitions; Sanofi's CEO picks a regulatory fight; Maine wants to allow Ex-US meds; and New York State seeks to empower pharmacists.

J&J OTC sales slipped 3% in 2012 worldwide

By

CEO Alex Gorsky said OTC brands are coming back. Meanwhile, pharmaceutical sales provided ballast to the year's numbers.

Branded drug spend up, but slower growth ahead

By

Last year, a wave of new products brought the industry succor as it awaits the full impact of the patent cliff on blockbuster brands. But companies should brace for contraction.

Company news: GlaxoSmithKline, AstraZeneca, Nature Publishing

GlaxoSmithKline is building its first new UK factory in almost 40 years, the firm said, spurring jobs while breaking new ground at some of its current locations.

As brand revenue shrinks, so does brand promotion

By

Branded drug sales declined 0.7% to $229 billion last year, according to IMS Health, and that's having an impact on promotional spend.

Which Pfizer brands could stay, go in a sell-off

Which Pfizer brands could stay, go in a sell-off

By

Pfizer may be headed toward a major restructuring that could include the sale of some of its most enduring brands, an analyst says.

Abbott's pharma unit retools as US boss retires

By

Abbott Labs' US pharmaceuticals business is undergoing some hefty changes: about 1,500 layoffs, a merger with the international division and the retirement of its SVP.

Federal appeals court overturns Vermont data ban

By

A federal appeals court on Tuesday reversed a district court ruling that limited the use of prescriber-identifiable data in Vermont, signaling a victory for plaintiffs IMS Health, SDI and Wolters Kluwer Health.

Roche details job cuts, passes Tamiflu to contract sales org

By

Roche detailed its "operational excellence" cost-cutting program in a statement today, which includes a reduction of 2,650 pharmaceutical sales and marketing jobs. In total, 6,300 jobs will be affected by the restructuring.

Few patients look to pharma sites for health info, survey says

By

Patients taking a medication and looking online for health information tend to avoid pharmaceutical company sites, according to an online survey conducted by Accenture.

DDMAC regulatory letters could double in 2010

By

New Year's Eve is five months away, but FDA letter-writers have already been prolific in 2010 on themes of risk omission, inflated efficacy claims, and unfair balance presentation as seen in promotional materials targeting physicians and consumers.

New PSAs promote pharma-funded online assessment tool

New PSAs promote pharma-funded online assessment tool

By

Public service announcements featuring Tyler Walker, a 20-year-old ankylosing spondylitis (AS) patient, direct back pain sufferers to an online test created to help identify undiagnosed AS patients. The test, and published research used to validate the test, was funded by Centocor, Abbott, Amgen and Pfizer.

Watson beefs up women's health biz, adds reps

By

Generics and specialty pharma Watson acquired a progesterone gel, marketed as Crinone and Prochieve, and added roughly 19 reps to its women's health sales force. Watson now employs close to 400 reps, according to Charlie Mayr, a company spokesperson.

PhRMA sweats Witty's EU samples cap

PhRMA sweats Witty's EU samples cap

By

PhRMA said the reasoning behind a sharp cap on samples mandated by its European counterpart doesn't apply in the US.

NASCAR driver Jeff Gordon to lead Sanofi whooping cough awareness campaign

NASCAR driver Jeff Gordon to lead Sanofi whooping cough awareness campaign

By

In an effort to throttle up awareness of whooping cough, or pertussis, Sanofi Pasteur and the March of Dimes have enlisted NASCAR driver Jeff Gordon to lead their ongoing Sounds of Pertussis campaign. Jennifer Lopez was previously the celebrity face of the campaign.

Viagra, Nexium and Chantix are Mensa-worthy brands, says digital IQ study

Viagra, Nexium and Chantix are Mensa-worthy brands, says digital IQ study

By

Marketers working on Pfizer brands Viagra and Chantix, and AstraZeneca's Nexium, can pat themselves on the back, since they all scored in the "genius" percentile based on digital marketing competency, according to the L2 Digital IQ Index.

Novartis announces new changes to US pharma biz

By

Following a full-scale realignment of its commercial model in 2009, Novartis will make new adjustments to its US pharmaceutical operations, including a change at the top: Ludwig Hantson, CEO and head of North American pharmaceuticals, will exit the company, a Novartis spokeswoman confirmed.

Aging Committee raps pharma on brand drug price hikes

Aging Committee raps pharma on brand drug price hikes

By

Armed with AARP and Kaiser Family research, members of the Senate Special Committee on Aging asked panelists why brand drug prices in the US continue to increase, while other countries pay half as much for the same products.

Juvederm Facebook campaign features Dayna Devon

Juvederm Facebook campaign features Dayna Devon

By

Allergan launched a celebrity Facebook campaign for Juvederm, on the heels of a new FDA approval for Juvederm XC, a formulation that contains lidocaine to make injections less painful.

Covidien, Biovail to beef up sales forces

By

While many sales jobs at large pharmaceutical companies continue to be shed amidst reorganizations, mergers and consolidations, Covidien and Biovail are bucking the trend and hiring new personnel.

Physician referral directory revamped for 2010

By

Doctors using The Little Blue Book for patient referrals will be able to decide how they want to use their thumbs -- for page turning or mobile app navigation -- when a revamped edition launches next quarter.

GSK launches surprising cervical cancer ads

GSK launches surprising cervical cancer ads

By

What began as a sparkly new ad for perfume quickly shifted gears, from trivial to terrifying, once the young female actor glimpsed the perfume bottle's script: cervical cancer.

Merck to consolidate media accounts

By

Merck will consolidate media duties on all of its brands, including the newly acquired Schering-Plough portfolio, after a review.

Novo reps to spotlight weight loss for Victoza launch

Novo reps to spotlight weight loss for Victoza launch

By

Sales forces for Novo Nordisk's Victoza will underscore the injectable's weight loss properties when it launches next month.

GSK relocates 2,200 sales positions as part of 'growth strategy'

GSK relocates 2,200 sales positions as part of 'growth strategy'

By

GlaxoSmithKline has put a twist on pharma's strategy of slashing sales reps to improve the earnings outlook, reallocating the positions to emerging markets.

Sanofi card trick draws warning

Sanofi card trick draws warning

By

A promotional card for Sanofi Aventis's Uroxatral omitted indication and risk information, and also used outdated product labeling, according to a DDMAC warning letter.

Merck discloses a portion of US speaker fees

By

On Monday, Merck disclosed fees paid to US-based medical and scientific professionals who spoke at promotional medical education programs during the third quarter of 2009.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.